Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.19 -4.8%	$3.28	$2.71 ▼ $4.73	$610.82M	1.5	999,659 shs	643,383 shs
AKBA Akebia Therapeutics	$2.48 +2.1%	$2.08	$0.80 ▼ $2.90	$649.23M	0.88	2.83 million shs	3.18 million shs
BIOA (BIOA)	$3.91 -15.8%	$0.00	$2.88 ▼ $26.62	$161.32M	N/A	490,772 shs	512,188 shs
DNTH Dianthus Therapeutics	$18.84 -6.2%	$19.68	$13.37 ▼ $32.27	$605.25M	1.48	267,034 shs	363,367 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-4.78%	-4.35%	+1.59%	-3.63%	+10.38%
AKBA Akebia Therapeutics	+2.06%	+6.90%	+50.30%	+17.54%	+92.25%
BIOA (BIOA)	-3.68%	-1.16%	+5.86%	-11.85%	+30,407.81%
DNTH Dianthus Therapeutics	-6.18%	-5.75%	+6.98%	-18.12%	-27.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.1451 of 5 stars	3.5	0.0	0.0	0.0	3.3	2.5	0.6
AKBA Akebia Therapeutics	4.1426 of 5 stars	4.6	2.0	0.0	4.0	2.1	0.0	0.6
BIOA (BIOA)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	1.2571 of 5 stars	3.6	0.0	0.0	0.0	2.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	72.41% Upside
AKBA Akebia Therapeutics	3.20	Buy	$6.63	167.14% Upside
BIOA (BIOA)	1.75	Reduce	$5.67	45.11% Upside
DNTH Dianthus Therapeutics	3.22	Buy	$53.00	181.32% Upside

Current Analyst Ratings Breakdown

Latest BIOA, DNTH, ABUS, and AKBA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	DNTH Dianthus Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $50.00
5/13/2025	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
4/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/1/2025	AKBA Akebia Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/24/2025	BIOA (BIOA)	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$7.00 ➝ $5.00
3/21/2025	BIOA (BIOA)	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/14/2025	AKBA Akebia Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$4.00 ➝ $6.00
3/14/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	98.98	N/A	N/A	$0.63 per share	5.06
AKBA Akebia Therapeutics	$160.18M	4.05	N/A	N/A	($0.16) per share	-15.50
BIOA (BIOA)	N/A	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	$6.24M	97.07	N/A	N/A	$11.40 per share	1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$72.85M	-$0.38	N/A	N/A	N/A	-1,137.65%	-68.18%	-51.55%	5/15/2025 (Estimated)
AKBA Akebia Therapeutics	-$51.92M	-$0.21	N/A	N/A	N/A	-27.07%	N/A	-20.57%	N/A
BIOA (BIOA)	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	-$43.56M	-$2.60	N/A	N/A	N/A	-1,250.32%	-21.68%	-20.88%	N/A

Latest BIOA, DNTH, ABUS, and AKBA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	N/A	N/A	N/A	$2.54 million	N/A
5/12/2025	Q1 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.82	+$0.04	-$0.82	$0.81 million	$1.16 million
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million
3/13/2025	Q4 2024	AKBA Akebia Therapeutics	-$0.05	-$0.10	-$0.05	-$0.10	$37.36 million	$46.50 million
3/11/2025	Q4 2024	DNTH Dianthus Therapeutics	-$0.85	-$0.81	+$0.04	-$0.81	$1.40 million	$1.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
BIOA (BIOA)	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	7.02	7.02
AKBA Akebia Therapeutics	N/A	1.52	1.21
BIOA (BIOA)	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	18.30	18.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
AKBA Akebia Therapeutics	33.92%
BIOA (BIOA)	N/A
DNTH Dianthus Therapeutics	47.53%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
AKBA Akebia Therapeutics	4.10%
BIOA (BIOA)	N/A
DNTH Dianthus Therapeutics	8.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.48 million	181.91 million	Optionable
AKBA Akebia Therapeutics	430	261.79 million	209.24 million	Optionable
BIOA (BIOA)	N/A	35.85 million	N/A	Not Optionable
DNTH Dianthus Therapeutics	80	32.13 million	24.70 million	Optionable

BIOA, DNTH, ABUS, and AKBA Headlines

Recent News About These Companies

4DNTH : Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views

May 13 at 6:10 PM | benzinga.com

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates

May 12 at 6:10 PM | zacks.com

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

May 12 at 4:01 PM | globenewswire.com

Braidwell LP Raises Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

May 8, 2025 | marketbeat.com

Dianthus Therapeutics completes enrollment for MaGic trial

May 6, 2025 | investing.com

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Avidity Partners Management LP

May 6, 2025 | marketbeat.com

Head-To-Head Survey: Dianthus Therapeutics (NASDAQ:DNTH) & Ascendis Pharma A/S (NASDAQ:ASND)

May 6, 2025 | americanbankingnews.com

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

May 5, 2025 | globenewswire.com

Allostery Investments LP Takes Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

May 4, 2025 | marketbeat.com

Ally Bridge Group NY LLC Buys New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

May 4, 2025 | marketbeat.com

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is 5AM Venture Management LLC's 6th Largest Position

May 4, 2025 | marketbeat.com

Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $54.33

May 4, 2025 | americanbankingnews.com

RA Capital Management L.P. Sells 466,600 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

May 3, 2025 | marketbeat.com

Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Buy" by Brokerages

May 3, 2025 | marketbeat.com

Adage Capital Partners GP L.L.C. Buys Shares of 180,000 Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

May 2, 2025 | marketbeat.com

TCG Crossover Management LLC Acquires Shares of 1,501,624 Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

May 1, 2025 | marketbeat.com

Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's What Happened

April 30, 2025 | marketbeat.com

Dianthus Therapeutics to Participate in Two Upcoming Investor Events

April 29, 2025 | globenewswire.com

Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.4% - Here's Why

April 23, 2025 | marketbeat.com

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Bain Capital Life Sciences Investors LLC

April 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA, DNTH, ABUS, and AKBA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.19 -0.16 (-4.78%)

As of 05/13/2025 04:00 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Akebia Therapeutics NASDAQ:AKBA

$2.48 +0.05 (+2.06%)

As of 05/13/2025 04:00 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

(BIOA) NYSE:BIOA

BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.

Dianthus Therapeutics NASDAQ:DNTH

$18.84 -1.24 (-6.18%)

As of 05/13/2025 04:00 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time